CEO Mark Kotter shares insights in an exclusive interview with Genetic Engineering & Biotechnology News about bit.bio's revolutionary CNS Tool Kit, a game-changer for CNS research and drug discovery.
Key Highlights:
Approach: Kotter discusses the shift from traditional directed differentiation methods to deterministic cell programming, significantly speeding up the process of creating human brain cells.
opti-ox: bit.bio’s proprietary deterministic programming technology allows for the rapid and consistent production of various brain cell types, including the newly launched ioAstrocytes, complementing the existing ioCells portfolio.
Building Brain Models: these cells can be combined to create detailed and customisable brain models, facilitating the study of cell interactions and disease mechanisms in a human context. ioAstrocytes and other brain cells can be co-cultured to facilitate brain complexity and disease mechanism modeling.
Access the article here.
